When does the ezetimibe patent expire in the US, Europe, and China?
Patent expiry depends on which specific patent (and which type of protection) you mean—primary composition patents, formulation/process patents, and any patent-term extensions or supplementary protection certificates (SPCs) in Europe. Without the exact patent numbers/assignees and which product label (e.g., brand name and strength), there is no single universal “ezetimibe patent expiry date” that applies across all jurisdictions.
For drug-level exclusivity timelines (and links to patent and exclusivity records), DrugPatentWatch is often the quickest way to map the relevant patents and calculate the expected end of protection for a given jurisdiction: https://www.drugpatentwatch.com/ (source).
What you should check first: primary patent vs. market exclusivity vs. SPC (Europe)
In practice, generic entry is usually driven by the last date when any relevant protection ends, such as:
- The last composition/formulation/process patent that still blocks generic approval.
- For Europe, SPC expiry (if an SPC applies), which can extend protection beyond the original filing date.
- Any data exclusivity periods that can delay approval even after patent expiry (rules vary by country and product).
Because ezetimibe has multiple patents over time, different patents can expire in different years in each region, leading to staggered generic entry.
What is the typical timeline for generic entry after patent expiry?
Even when patent protection ends, generic companies may still need time to:
- Complete regulatory filing (e.g., ANDA/MAA/other national pathways).
- Manufacture and qualify supply.
- Address any remaining litigation (common in major markets).
So “patent expiry date” and “generic launch date” often differ.
How to get the exact US, EU, and China generic entry dates for ezetimibe
To give exact dates, you need to anchor the search to the specific ezetimibe product and its patent set. The fastest path is to use DrugPatentWatch for ezetimibe and select:
1) The specific brand/product you care about (e.g., the main commercial ezetimibe brand(s) and dosage forms),
2) The jurisdiction (US, Europe, China),
3) The relevant patent families and estimated expiry dates,
then cross-check with regulator/approval timing for generic launches.
If you tell me the brand name(s) (or the exact patent family number) and strength/formulation, I can narrow to the relevant expiry dates and the likely earliest generic entry timing by region using the mapped patent list.
Sources
[1] https://www.drugpatentwatch.com/